Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Universe of Impeccable Pearls: A Manual for Valuable Gems - 2When the moon hits your eye from your Orion ship up high, that's a 'mare'
- 3A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
- 4Rediscovering Experience Through Excursions: Individual Travel Stories
- 5France, Germany, Italy summon Iranian envoys over 'unbearable, inhumane' regime crackdown
- Monetary Freedom Guide: Plan Your Future
- Record-breaking flu hospitalizations in New York in a single week: Health officials
- Careful Nurturing: Techniques for Bringing up Tough Children
- 5 Most Expected Film Delivery
- 5 Arising Professions in Environmentally friendly power
- Flat Earth, spirits and conspiracy theories – experience can shape even extraordinary beliefs
- Living Abroad: Social Inundation and Self-improvement
- Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis
- Huge rotating structure of galaxies and dark matter is detected
